Zhejiang Conba Pharmaceutical Co (SHSE:600572) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600572 Zhejiang Conba Pharmaceutical Co Ltd SHSE:600572
71 GF Score
Price ¥4.32
GF Value ¥5.51
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Zhejiang Conba Pharmaceutical Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zhejiang Conba Pharmaceutical Co Valuation Rank Related Terms

SHSE:600572
71GF Score
Zhejiang Conba Pharmaceutical Co Ltd SHSE:600572
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥4.32 is trading 21.6% below its estimated GF Value™ of ¥5.51. GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600572:

  • Valuation Rank:
  • GF Value™: ¥5.51 vs. price of ¥4.32 (21.6% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Conba Pharmaceutical Co Business Description

Address No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
71GF Score

Get the complete analysis for SHSE:600572

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.32
Price
¥5.51
GF Value